Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Merck enters $2B licensing deal for weight loss drug
